Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 3,485 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Rahul D. Ballal sold 3,485 shares of Enliven Therapeutics stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $19.15, for a total value of $66,737.75. Following the transaction, the director now owns 22,341 shares of the company’s stock, valued at approximately $427,830.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Enliven Therapeutics Stock Down 5.7 %

Shares of NASDAQ:ELVN traded down $1.10 on Monday, hitting $18.30. 87,392 shares of the company traded hands, compared to its average volume of 145,954. The company has a market cap of $753.96 million, a PE ratio of -8.36 and a beta of 1.06. The stock has a 50 day simple moving average of $16.37 and a 200-day simple moving average of $14.00. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $23.83.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. As a group, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -2.14 earnings per share for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC bought a new position in shares of Enliven Therapeutics in the 1st quarter worth approximately $158,000. Bank of New York Mellon Corp bought a new position in shares of Enliven Therapeutics in the 1st quarter worth approximately $335,000. Tower Research Capital LLC TRC bought a new position in shares of Enliven Therapeutics in the 1st quarter worth approximately $36,000. Citigroup Inc. bought a new position in shares of Enliven Therapeutics in the 1st quarter worth approximately $247,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Enliven Therapeutics in the 1st quarter worth approximately $217,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.